US Patent

US12295940 — Viral inhibitors, the synthesis thereof, and intermediates thereto

Composition of Matter · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2043-10-11 · 17y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects the composition of maribavir, a benzimidazole riboside used as an orally available antiviral medication against cytomegalovirus (CMV).

USPTO Abstract

The present disclosure discloses compositions comprising maribavir, methods of providing the same, and compositions providing intermediates useful in providing maribavir. Maribavir (((2S,3S,4R,5S)-2-(5,6-dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol) is a benzimidazole riboside and is an orally available antiviral medication against cytomegalovirus (CMV).

Drugs covered by this patent

Patent Metadata

Patent number
US12295940
Jurisdiction
US
Classification
Composition of Matter
Expires
2043-10-11
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.